Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AS03-adjuvanted H7N9 Vaccine with Seasonal Influenza Vaccine
NCT03318315Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2018
- Primary completion
- Jul 2019
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of inactivated influenza H7N9 vaccine in Avian Influenza (AI), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2018; status: completed.
02
Drugs
inactivated influenza H7N9 vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03318315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318315.